Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.06.19
Views: 517
Rating:

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Prof Matthew Galsky talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the HCRN GU14-182 Phase II study.

He describes how the trail aims to extend PFS through switch maintenance with immune checkpoint blockade, and the results were positive with the expected toxicities.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation